Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Sodium Iodide | HCID 5238 | — |
| Reactant | Cesium carbonate | HCID 10796 | — |
| Reactant | 2-Bromoacetamide | HCID 69632 | — |
| Reactant | HCID 86614401 | HCID 86614401 | — |
| Solvent | Acetone | HCID 180 | — |
| Solvent | Diethyl Ether | HCID 3283 | — |
| Product | HCID 86614402 | HCID 86614402 | 70.3% |
Reaction Steps
To a solution of 4-[2-(4-{(E)-3-[1-{[4-(benzyloxy-carbonyl)piperazin-1-yl]carbonyl}-1-(methyl)ethyl-carbamoyl]prop-1-enyl}phenyl)ethynyl]-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-indazole (73 mg) in acetone (4 mL) were added 2-bromoacetoamide (18 mg), cesium carbonate (54 mg) and a catalytic amount of sodium iodide, and the mixture was stirred at room temperature for5 hours. The reaction mixture was diluted with diethyl ether, and the resulting mixture was washed with water twice and brine, and dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (eluent:dichloromethane/methanol=40/1-30/1) to give 4-[2-(4-{(E)-3-[1-{[4-(benzyloxycarbonyl)piperazin-1-yl]carbonyl}-l-(methyl)ethylcarbamoyl]prop-l-enyl}-phenyl)ethynyl]-1-carbamoylmethyl-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-indazole (54 mg). The title compound (10 mg) was prepared in a similar manner to that described in Example 109 using this material as the starting material.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US07375113B2 |
|---|
| Source dataset | uspto-grants-2008_05 |
|---|
| ORD ID | ord-a0b61b7113f943619623cf98db7e6563 |
|---|
| Source note | uspto-grants-2008_05 |
|---|